Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
Key TakeawaysA Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.Concerns were ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...